Laurus nobilis L. seed extract reveals collateral sensitivity in multidrug-resistant P-glycoprotein-expressing tumor cells

Nutrition and Cancer

Volumn 67, Issue 4, 2015, Pages 664-675

  Saab, Antoine M ^a   Guerrini, Alessandra ^b   Zeino, Maen ^c   Wiench, Benjamin ^c   Rossi, Damiano ^b   Gambari, Roberto ^b   Sacchetti, Gianni ^b   Greten, Henry Johannes ^d,e   Efferth, Thomas ^c  

^a LEBANESE UNIVERSITY   (Lebanon)

^b UNIVERSITY OF FERRARA   (Italy)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d UNIVERSITY OF PORTO   (Portugal)

^e Heidelberg School of Chinese Medicine   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CINEOLE; DECANOIC ACID; DOXORUBICIN; ELAIDIC ACID; LAURIC ACID; LIMONENE; LINOLEIC ACID; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MYRISTIC ACID; OLEIC ACID; PALMITIC ACID; RHODAMINE; STEARIC ACID; ABCB1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; PLANT EXTRACT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; COMPARATIVE STUDY; DRUG SENSITIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC50; LAURUS NOBILIS; LEUKEMIA CELL; MASS FRAGMENTOGRAPHY; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; PLANT SEED; PROTON NUCLEAR MAGNETIC RESONANCE; TUMOR CELL; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; LAURUS; LEUKEMIA; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

LAURUS NOBILIS;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; CELL SURVIVAL; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; LAURUS; LEUKEMIA; P-GLYCOPROTEINS; PLANT EXTRACTS; SEEDS;

EID: 84929130892     PISSN: 01635581     EISSN: 15327914     Source Type: Journal    
DOI: 10.1080/01635581.2015.1019632     Document Type: Article

References (57)

1. Gottesman MM and Ling V: The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research. FEBS Lett 580, 998-1009, 2006.
2. Efferth T: The human ATP-binding cassette transporter genes: from the bench to the bedside. Curr Mol Med 1, 45-65, 2001.
3. Gillet JP, Efferth T, and Remacle J: Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochim Biophys Acta 1775, 237-262, 2007.
4. Tsuruo T, Iida H, Tsukagoshi S, and Sakurai Y: Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41, 1967-1972, 1981.
5. Ford JM and Hait WN: Pharmacologic circumvention of multidrug resistance. Cytotechnology 12, 171-212, 1993.
6. Tiwari AK, Sodani K, Dai CL, Ashby CR, Jr., and Chen ZS: Revisiting the ABCs of multidrug resistance in cancer chemotherapy. Curr Pharm Biotechnol 12, 570-594, 2011.
7. Amiri-Kordestani L, Basseville A, Kurdziel K, Fojo AT, and Bates SE: Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies. Drug Resist Updat 15, 50-61, 2012.
8. Eichhorn T and Efferth T: P-glycoprotein and its inhibition in tumors by phytochemicals derived from Chinese herbs. J Ethnopharmacol 141, 557-570, 2012.
9. Volm M, Efferth T, Gunther A, and Lathan B: Detection of murine S180 cells expressing a multidrug resistance phenotype using different in vitro test systems and a monoclonal antibody. Arzneimittelforschung 37, 862-867, 1987.
10. van Triest B, Pinedo HM, Telleman F, van der Wilt CL, Jansen G, et al.: Cross-resistance to antifolates in multidrug resistant cell lines with P-glycoprotein or multidrug resistance protein expression. Biochem Pharmacol 53, 1855-1866, 1997.
11. Hall MD, Handley MD, and Gottesman MM: Is resistance useless? Multidrug resistance and collateral sensitivity. Trends Pharmacol Sci 30, 546-556, 2009.
12. Saeed MGJ and Efferth T: Collateral sensitivity in drug-resistant tumor cells. In: Tumor Cell Resistance to Apoptosis by Cytotoxic Drugs and Reversal of Resistance by Targeted Sensitizing Cells, Bonavida B (ed.). New York: Springer, 2013, pp. 187-211.
13. Horwedel C, Tsogoeva SB, Wei S, and Efferth T: Cytotoxicity of artesunic acid homo-and heterodimer molecules toward sensitive and multidrug-resistant CCRF-CEM leukemia cells. J Med Chem 53, 4842-4848, 2010.
14. Reiter C, Herrmann A, Capci A, Efferth T, and Tsogoeva SB: New artesunic acid homodimers: potent reversal agents of multidrug resistance in leukemia cells. Bioorg Med Chem 20, 5637-5641, 2012.
15. Kuete V, Tchakam PD, Wiench B, Ngameni B, Wabo HK, et al.: Cytotoxicity and modes of action of four naturally occuring benzophenones: 2,2',5,6'-tetrahydroxybenzophenone, guttiferone E, isogarcinol and isoxanthochymol. Phytomedicine 20, 528-536, 2013.
16. Kuete V, Sandjo LP, Wiench B, and Efferth T: Cytotoxicity and modes of action of four Cameroonian dietary spices ethno-medically used to treat cancers: Echinops giganteus, Xylopia aethiopica, Imperata cylindrica and Piper capense. J Ethnopharmacol 149, 245-253, 2013.
17. Kuete V, Sandjo LP, Ouete JL, Fouotsa H, Wiench B, et al.: Cytotoxicity and modes of action of three naturally occurring xanthones (8-hydroxycudraxanthone G, morusignin I and cudraxanthone I) against sensitive and multidrug-resistant cancer cell lines. Phytomedicine 21, 315-322, 2014.
18. Kuete V, Ango PY, Yeboah SO, Mbaveng AT, Mapitse R, et al.: Cytotoxicity of four Aframomum species (A. arundinaceum, A. alboviolaceum, A. kayserianum and A. polyanthum) towards multi-factorial drug resistant cancer cell lines. BMC Complement Altern Med 14, 340, 2014.
19. Kuete V, Sandjo LP, Djeussi DE, Zeino M, Kwamou GM, et al.: Cytotoxic flavonoids and isoflavonoids from Erythrina sigmoidea towards multi-factorial drug resistant cancer cells. Invest New Drugs 32, 1053-1062, 2014.
20. Hamm R, Sugimoto Y, Steinmetz H, and Efferth T: Resistance mechanisms of cancer cells to the novel vacuolar H(C)-ATPase inhibitor archazolid B. Invest New Drugs 32, 893-903, 2014.
21. Afifi FU, Khalil E, Tamimi SO, and Disi A: Evaluation of the gastroprotective effect of Laurus nobilis seeds on ethanol induced gastric ulcer in rats. J Ethnopharmacol 58, 9-14, 1997.
22. Loizzo MR, Tundis R, Menichini F, Saab AM, and Statti GA: Cytotoxic activity of essential oils from labiatae and lauraceae families against in vitro human tumor models. Anticancer Res 27, 3293-3299, 2007.
23. Saab AM, Tundis R, Loizzo MR, Lampronti I, Borgatti M, et al.: Antioxidant and antiproliferative activity of Laurus nobilis L. (Lauraceae) leaves and seeds essential oils against K562 human chronic myelogenous leukaemia cells. Nat Prod Res 26, 1741-1745, 2012.
24. Saab AMLI, Grandini A, Borgatti M, Finotti A, Sacchetti G, et al.: Antiproliferative and erythoid differentiation activities of Cedrus libani seed extracts against K562 human chronic myelogenous leukemia cells. Int J Pharm Biol Arch 2, 1658-1662, 2011.
25. Rossi DGA, Maietti S, Bruni R, Paganetto G, Poli F, et al.: Chemical fingerprinting and bioactivity of Amazonian Ecuador Croton lechleri Mull. Arg. (Euphorbiaceae) stem bark essential oil: a new functional food ingredient? Food Chemistry 126, 837-848, 2011.
26. Kimmig A, Gekeler V, Neumann M, Frese G, Handgretinger R, et al.: Susceptibility of multidrug-resistant human leukemia cell lines to human interleukin 2-activated killer cells. Cancer Res 50, 6793-6799, 1990.
27. Efferth T, Sauerbrey A, Olbrich A, Gebhart E, Rauch P, et al.: Molecular modes of action of artesunate in tumor cell lines. Mol Pharmacol 64, 382-394, 2003.
28. Gillet JP, Efferth T, Steinbach D, Hamels J, de Longueville F, et al.: Microarray-based detection of multidrug resistance in human tumor cells by expression profiling of ATP-binding cassette transporter genes. Cancer Res 64, 8987-8993, 2004.
29. O'Brien J, Wilson I, Orton T, and Pognan F: Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur J Biochem 267, 5421-5426, 2000.
30. Kuete V, Wiench B, Hegazy ME, Mohamed TA, Fankam AG, et al.: Antibacterial activity and cytotoxicity of selected Egyptian medicinal plants. Planta Med 78, 193-199, 2012.
31. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, et al.: Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 83, 757-766, 1991.
32. Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, et al.: A gene expression database for the molecular pharmacology of cancer. Nat Genet 24, 236-244, 2000.
33. Amundson SA, Do KT, Vinikoor LC, Lee RA, Koch-Paiz CA, et al.: Integrating global gene expression and radiation survival parameters across the 60 cell lines of the National Cancer Institute Anticancer Drug Screen. Cancer Res 68, 415-424, 2008.
34. Efferth T, Fabry U, and Osieka R: Apoptosis and resistance to daunorubicin in human leukemic cells. Leukemia 11, 1180-1186, 1997.
35. Ok S: Fast screening of Turkish olive oil by NMR spectroscopy for geographical determination and discrimination purposes. Grasas Aceites 65(2), e024, 2014.
36. Sacchi R, Addeo F, and Paolilllo L: 1H and 13C NMR of virgin olive oil. An overview. Magn Reson Chem 35, S133-S145, 1997.
37. Marzouki HMH, Khaldi AH, Koujia ML, Piras A, Giordano E, Cet al.: Fatty acid composition, essential oil, and antibacterial activity of berries of Laurus nobilis L. J Essent Oil Bear Pl 12, 422-434, 2009.
38. Mahringer A, Karamustafa S, Klotz D, Kahl S, Konkimalla VB, et al.: Inhibition of P-glycoprotein at the blood-brain barrier by phytochemicals derived from traditional Chinese medicine. Cancer Genomics Proteomics 7, 191-205, 2010.
39. Efferth T, Konkimalla VB, Wang YF, Sauerbrey A, Meinhardt S, et al.: Prediction of broad spectrum resistance of tumors towards anticancer drugs. Clin Cancer Res 14, 2405-2412, 2008.
40. Goldsborough AS, Handley MD, Dulcey AE, Pluchino KM, Kannan P, et al.: Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin. J Med Chem 54, 4987-4997, 2011.
41. Pluchino KM, Hall MD, Goldsborough AS, Callaghan R, and Gottesman MM: Collateral sensitivity as a strategy against cancer multidrug resistance. Drug Resist Updat 15, 98-105, 2012.
42. Efferth T and Koch E: Complex interactions between phytochemicals. The multi-target therapeutic concept of phytotherapy. Curr Drug Targets 12, 122-132, 2011.
43. Efferth T, Miyachi H, Drexler HG, and Gebhart E: Methylthioadenosine phosphorylase as target for chemoselective treatment of T-cell acute lymphoblastic leukemic cells. Blood Cells Mol Dis 28, 47-56, 2002.
44. Efferth T, Verdorfer I, Miyachi H, Sauerbrey A, Drexler HG, et al.: Genomic imbalances in drug-resistant T-cell acute lymphoblastic CEM leukemia cell lines. Blood Cells Mol Dis 29, 1-13, 2002.
45. Villeneuve DJ and Parissenti AM: The use of DNA microarrays to investigate the pharmacogenomics of drug response in living systems. Curr Top Med Chem 4, 1329-1345, 2004.
46. Zeeberg BR, Liu H, Kahn AB, Ehler M, Rajapakse VN, et al.: RedundancyMiner: De-replication of redundant GO categories in microarray and proteomics analysis. BMC Bioinformatics 12, 52, 2011.
47. Reinhold WC, Sunshine M, Liu H, Varma S, Kohn KW, et al.: CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. Cancer Res 72, 3499-3511, 2012.
48. Efferth T: Personalized cancer medicine: from molecular diagnostics to targeted therapy with natural products. Planta Med 76, 1143-1154, 2010.
49. Efferth T: Stem cells, cancer stem-like cells, and natural products. Planta Med 78, 935-942, 2012.
50. Efferth T: Signal transduction pathways of the epidermal growth factor receptor in colorectal cancer and their inhibition by small molecules. Curr Med Chem 19, 5735-5744, 2012.
51. Estey E. Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol 25, 1908-1915, 2007.
52. Ko RH, Ji L, Barnette P, Bostrom B, Hutchinson R, et al.: Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study. J Clin Oncol 28, 648-654, 2010.
53. Bassan R and Hoelzer D: Modern therapy of acute lymphoblastic leukemia. J Clin Oncol 29, 532-543, 2011.
54. Ghadimi BM, Grade M, Difilippantonio MJ, Varma S, Simon R, et al:. Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. J Clin Oncol 23, 1826-1838, 2005.
55. Kim IJ, Lim SB, Kang HC, Chang HJ, Ahn SA, et al.: Microarray gene expression profiling for predicting complete response to preoperative chemoradiotherapy in patients with advanced rectal cancer. Dis Colon Rectum 50, 1342-1353, 2007.
56. Swanton C, Szallasi Z, Brenton JD, and Downward J: Functional genomic analysis of drug sensitivity pathways to guide adjuvant strategies in breast cancer. Breast Cancer Res 10, 214, 2008.
57. Saeed MKH, Sugimoto Y, and Efferth T: The lignan, (-)-sesamin reveals cytotoxicity towards cancer cells: pharmacogenomic determination of genes associated with sensitivity or resistance. Phytomedicine 21, 689-696, 2014.